marijuana stocks news

Form 8-K for CV SCIENCES, INC.


11-Feb-2016

Regulation FD Disclosure

Item 7.01 Regulation FD DisclosureOn February 9, 2016, CV Sciences, Inc. formerly CannaVEST Corp. (the “Company”) issued a press release (the “Press Release”) regarding the rejection of the Company’s prepayment by one investor who acquired certain convertible promissory notes issued by the Company by assignment from the lead investor. A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and, as a result, such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Curaleaf Holdings, Inc. (CURLF) Expands its Presence in Three Key Growth Markets with Acquisition of Tryke Companies

Curaleaf Expands its Presence in Three Key Growth Markets with Acquisition of…

PotNetwork Holding, Inc. (POTN) April Revenues Blow Away Expectations

$1,007,797.87 April Revenues Blow Away Expectations as PotNetwork Holding Continues to Exceed…

 American Green (ERBB) Hits Operational Breakeven in 2020

American Green Hits Operational Breakeven in 2020    American Green (ERBB:OTC) is proud…

GT Biopharma Inc. (GTBP) Starts FDA Phase 1 Clinical Trial for Myasthenia Gravis Autoimmune Muscular Disease

GT Biopharma, Inc. Starts FDA Phase 1 Clinical Trial for Myasthenia Gravis…